Established strategic plan to become the preferred drug delivery partner for specific infusion therapies in select markets
Net Revenue increased 12.4% to $17.4 million from $15.4 million
Adjusted EBITDA* expanded to $2.7 million, up 73.9% from $1.6 million in 2017
This presentation contains forward-looking statements that involve risks and uncertainties, including but not limited to those related to the growth of the home infusion market, our SG&A expenditures and the potential for Nasdaq uplisting. Actual results and events may differ significantly from results and events discussed in the forward-looking statements. Factors that might cause or contribute to such differences include, but are not limited to, economic and business conditions, trends and events around the world and in the markets in which RMS operates, competitive pressure, customer acceptance of new products, changes in medical reimbursement regulations, regulatory approvals for new products, foreign regulations governing medical devices, introduction of new technologies and those discussed in our Transition Report on Form 10-K for the fiscal year ended December 31, 2017. We undertake no obligation to update publicly this presentation or any forward-looking statements to reflect new information, events, or circumstances after the hereof.